PARTNERSHIP OPPORTUNITIES
SDS-PAGE Analysis of Purified Monospecific Mouse Monoclonal Antibody to VISTA (VISTA/2864). Confirmation of Integrity and Purity of Antibody.
Analysis of Protein Array containing more than 19,000 full-length human proteins using Monospecific Mouse Monoclonal Antibody to VISTA (VISTA/2864). Z- and S- Score: The Z-score represents the strength of a signal that a monoclonal antibody (Monoclonal Antibody) (in combination with a fluorescently-tagged anti-IgG secondary antibody) produces when binding to a particular protein on the HuProtTM array. Z-scores are described in units of standard deviations (SD’s) above the mean value of all signals generated on that array. If targets on HuProtTM are arranged in descending order of the Z-score, the S-score is the difference (also in units of SD’s) between the Z-score. S-score therefore represents the relative target specificity of a Monoclonal Antibody to its intended target. A Monoclonal Antibody is considered to specific to its intended target, if the Monoclonal Antibody has an S-score of at least 2.5. For example, if a Monoclonal Antibody binds to protein X with a Z-score of 43 and to protein Y with a Z-score of 14, then the S-score for the binding of that Monoclonal Antibody to protein X is equal to 29.
VISTA / GI24 is a transmembrane protein expressed in bone, on embryonic stem cells (ESCs), and on tumor cell surfaces. On ESC s, Gi24 appears to positively interact with BMP-4, potentiating BMP signaling and the transition from an undifferentiated to a differentiated state. On tumor cells, Gi24 both promotes MT1-MMP expression and activity and serves as a substrate for MT1-MMP. This increases the potential for cell motility. Mature human Gi24 contains a 162aa extracellular region with one V-type Ig-like domain and a 96aa cytoplasmic domain. Human Gi24 undergoes proteolytic cleavage by MT1-MMP, generating a soluble 30kDa extracellular fragment plus a 25-30kDa membrane-bound fragment. VISTA is a negative checkpoint regulator and is expressed on myeloid cells, T-cells and human TILs (tumor infiltrating lymphocytes) on MDSCs (myeloid-derived suppressor cells) in the TME (tumor microenvironment). It is very likely both a ligand and receptor and is a promising target for cancer immunotherapy.
There are no reviews yet.